Anti-inflammatory treatment for major depressive disorder: Implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy

Journal of Psychopharmacology

Volumn 31, Issue 9, 2017, Pages 1149-1165

  Kopschina Feltes, Paula ^a,b   Doorduin, Janine ^a   Klein, Hans C ^a   Juárez Orozco, Luis Eduardo ^a   Dierckx, Rudi A J O ^a   Moriguchi Jeckel, Cristina M ^b   De Vries, Erik F J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antidepressants; Major depressive disorder; Microglia; Neuroinflammation; Pro inflammatory cytokines

Indexed keywords

ANTIDEPRESSANT AGENT; CELECOXIB; CITALOPRAM; CYCLIC AMP; CYTOKINE; ESCITALOPRAM; FLUOXETINE; GAMMA INTERFERON; IMIPRAMINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MIRTAZAPINE; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; QUINOLINIC ACID; REBOXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT;

ADD ON THERAPY; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; COMORBIDITY; CONNECTOME; CYTOKINE RELEASE; ENDOCRINE DISEASE; ENZYME ACTIVITY; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; IMMUNE DYSREGULATION; INFECTION; INFLAMMATION; INSOMNIA; MACROPHAGE ACTIVATION; MAJOR DEPRESSION; MENTAL PATIENT; MICROGLIA; MONOAMINE METABOLISM; MONOTHERAPY; NAUSEA; NONHUMAN; NORADRENERGIC SYSTEM; OBESITY; PATHOPHYSIOLOGY; PATIENT PARTICIPATION; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SEROTONIN LEVEL; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; STIMULUS; THERAPY RESISTANCE; THROMBOSIS; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; DRUG EFFECT; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; PITUITARY-ADRENAL SYSTEM; SEROTONIN;

EID: 85027967167     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881117711708     Document Type: Review

References (170)

1. Abbasi S-H, Hosseini F, Modabbernia A, et al. (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affective Disorders 141: 308-314.
2. Aïd S, Bosetti F, (2011) Targeting cyclooxygenases-1 and-2 in neuroinflammation: Therapeutic implications. Biochimie 93: 46-51.
3. Aid S, Langenbach R, Bosetti F, (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 5: 1-14.
4. Akhondzadeh S, Jafari S, Raisi F, et al. (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo-controlled trial. Depress Anxiety 26: 607-611.
5. Alboni S, Benatti C, Montanari C, et al. (2013) Chronic antidepressant treatments resulted in altered expression of genes involved in inflammation in the rat hypothalamus. Eur J Pharmacol 721: 158-167.
6. Alboni S, Cervia D, Sugama S, et al. (2010) Interleukin 18 in the CNS. J Neuroinflammation 7: 1-12.
7. Almeida OP, Alfonso H, Jamrozik K, et al. (2010) Aspirin use, depression and cognitive impairment in later life: The Health in Men Study. J Am Geriatr Soc 58: 990-992.
8. Almeida OP, Flicker L, Yeap BB, et al. (2012) Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2: e151.
9. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, TX: American Psychiatric Publishing.
10. Anders S, Tanaka M, Kinney DK, (2013) Depression as an evolutionary strategy for defense against infection. Brain Behav Immun 31: 9-22.
11. Anderson G, Kubera M, Duda W, et al. (2013) Increased IL-6 trans-signaling in depression: Focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep 65: 1647-1654.
12. Bah TM, Benderdour M, Kaloustian S, et al. (2011) Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behav Brain Res 225: 243-251.
13. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. (2002) Selective serotonin reuptake inhibitors and the risk of stroke: A population-based case-control study. Stroke 33: 1465-1473.
14. Basterzi AD, Aydemir Ç Kisa C, et al. (2005) IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 20: 473-476.
15. Beishuizen A, Thijs LG, (2003) Endotoxin and the hypothalamo-pituitary-Adrenal (HPA) axis. J Endotoxin Res 9: 3-24.
16. Blais V, Turrin NP, Rivest S, (2005) Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem 95: 1563-1574.
17. Bombardier C, Laine L, Reicin A, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528.
18. Brunello N, Alboni S, Capone G, et al. (2006) Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 21: 219-225.
19. Brunoni AR, Machado-Vieira R, Zarate CA, et al. (2014) Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) 231: 1315-1323.
20. Bryleva EY, Brundin L, (2017) Kynurenine pathway metabolites and suicidality. Neuropharmacology 112: 324-330.
21. Bschor T, Ising M, Erbe S, et al. (2012) Impact of citalopram on the HPA system. A study of the combined DEX/CRH test in 30 unipolar depressed patients. J Psychiatr Res 46: 111-117.
22. Carvalho L, Torre J, Papadopoulos A, et al. (2013) Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disorders 148: 136-140.
23. Casolini P, Catalani A, Zuena AR, et al. (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68: 337-343.
24. Cavanagh J, Paterson C, McLean J, et al. (2010) Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: A clinical, proof-of-concept study. Ann Rheum Dis 69: 1251-1252.
25. Chen C, Tzeng N, Chen Y, (2010) Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry 32: 647.e7-647.e9.
26. Choi S, Langenbach R, Bosetti F, (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J 22: 1491-1501.
27. Chu C-S, Chou P-H, Lin C-H, et al. (2016) Use of selective serotonin reuptake inhibitors and risks of stroke in patients with obsessive compulsive disorder: A population-based study. PLoS One 11: e0162239.
28. Czeh M, Gressens P, Kaindl AM, (2011) The yin and yang of microglia. Dev Neurosci 33: 199-209.
29. Dantzer R, O'Connor JC, Freund GG, et al. (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
30. Dantzer R, O'Connor JC, Lawson MA, et al. (2011) Inflammation-Associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36: 426-436.
31. Dobos N, de Vries EFJ, Kema IP, et al. (2012) The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis 28: 905-915.
32. Doorduin J, de Vries EFJ, Dierckx RA, et al. (2008) PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr Pharm Des 14: 3297-3315.
33. Dowlati Y, Herrmann N, Swardfager W, et al. (2010) A meta-Analysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
34. Eller T, Vasar V, Shlik J, et al. (2008) Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32: 445-450.
35. Eller T, Vasar V, Shlik J, et al. (2009) Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J Psychopharmacol 23: 854-858.
36. Faridhosseini F, Sadeghi R, Farid L, et al. (2014) Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-Analysis of randomized placebo-controlled trials. Hum Psychopharmacol 29: 216-223.
37. Ferguson JM, (2001) SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3: 22-27.
38. Fields C, Drye L, Vaidya V, et al. (2012) Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial. Am J Geriatr Psychiatry 20: 505-513.
39. Frick LR, Williams K, Pittenger C, (2013) Microglial dysregulation in psychiatric disease. Clin Dev Immunol 2013: 608654.
40. Friedman A, (2014) Jump-starting natural resilience reverses stress susceptibility. Science 346: 555.
41. Funk C, FitzGerald G, (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharm 50: 470-479.
42. GaAecki P, Gaaecka E, Maes M, et al. (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disorders 138: 360-366.
43. Guillemin GJ, (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279: 1356-1365.
44. Guloksuz S, Rutten BPF, Arts B, et al. (2014) The immune system and electroconvulsive therapy for depression. J ECT 30: 132-137.
45. Guo J-Y, Li C-Y, Ruan Y-P, et al. (2009) Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 612: 54-60.
46. Haaland DA, Sabljic TF, Baribeau DA, et al. (2008) Is regular exercise a friend or foe of the aging immune system? A systematic review. Clin J Sport Med 18: 539-548.
47. Hamilton M, (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
48. Hannestad J, DellaGioia N, Bloch M, (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-Analysis. Neuropsychopharmacology 36: 2452-2459.
49. Hannestad J, DellaGioia N, Gallezot J, et al. (2013) The neuroinflammation marker translocator protein is not elevated in individuals with mild-To-moderate depression: A [11C]PBR28 PET study. Brain Behav Immun 33: 131-138.
50. Harden L, Kent S, Pittman Q, et al. (2015) Fever and sickness behavior: friend or foe? Brain Behav Immun 50: 322-333.
51. Haroon E, Raison CL, Miller AH, (2012) Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37: 137-162.
52. Hasler G, (2010) Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry 9: 155-161.
53. Hawkey C, (2003) Non-steroidal anti-inflammatory drugs: overall risks and management. complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52: 600-608.
54. Hernandez ME, Mendieta D, Martínez-Fong D, et al. (2008) Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 18: 917-924.
55. Howren MB, Lamkin DM, Suls J, (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-Analysis. Psychosom Med 71: 171-186.
56. Iyengar RL, Gandhi S, Aneja A, et al. (2013) NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med 126: 1017. e11-e18.
57. Johnson RW, (2015) Feeding the beast: can microglia in the senescent brain be regulated by diet? Brain Behav Immun 43: 1-8.
58. Jokela M, Virtanen M, Batty GD, et al. (2015) Inflammation and specific symptoms of depression. JAMA Psychiatry 73: 87-88.
59. Kearney PM, Baigent C, Godwin J, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-Analysis of randomised trials. BMJ 332: 1302-1308.
60. Kemp DE, (2014) Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disorders 169: S34-S44.
61. Kessler RC, Berglund P, Demler O, et al. (2003) The epidemiology of major depressive disorder. JAMA 289: 3095-3105.
62. Kim H, Chen L, Lim G, et al. (2012) Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 122: 2940-2954.
63. Kim Y, Lee S, Kim S, et al. (2008) Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 32: 356-361.
64. Köhler O, Benros ME, Nordentoft M, et al. (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry 71: 1381.
65. Kreisel T, Frank MG, Licht T, et al. (2014) Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatr 19: 699-709.
66. Krogh J, Benros ME, Jørgensen MB, et al. (2014) The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun 35: 70-76.
67. Kurhe Y, Mahesh R, Gupta D, (2014) Effect of a selective cyclooxigenase type 2 inhibitor celecoxib on depression associated with obesity in mice: An approach using behavioral tests. Neurochem Res 39: 1395-1402.
68. Lanquillon S, Krieg J-C, Bening-Abu-Shach U, et al. (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol 22: 370-379.
69. Lavretsky H, Alstein LL, Olmstead RE, et al. (2011) Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: A randomized controlled trial. Am J Geriatr Psychiatry 19: 839-850.
70. Leo R, Di Lorenzo G, Tesauro M, et al. (2006) Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder. J Clin Psychiatry 67: 1760-1766.
71. Liu H, Luiten P, Eisel U, et al. (2013) Depression after myocardial infarction: TNF-α-induced alterations of the blood-brain barrier and its putative therapeutic implications. Neurosci Biobehav Rev 37: 561-572.
72. Loftis JM, Huckans M, Morasco BJ, (2010) Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 37: 519-533.
73. Luppino FS, de Wit LM, Bouvy PF, et al. (2010) Overweight, obesity, and depression. Arch Gen Psychiatry 67: 220-229.
74. Maciel IS, Silva RBM, Morrone FB, et al. (2013) Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice. PLoS One 8: e77227.
75. Maes M, (1995) Evidence for an immune response in major depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19: 11-38.
76. Maes M, (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 664-675.
77. Maes M, (2012) Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and. even aggravate the pathophysiology underpinning depression. Metab Brain Dis 27: 405-413.
78. Maes M, Berk M, Goehler L, et al. (2012) Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10: 66.
79. Maes M, Bosmans E, De Jongh R, et al. (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9: 853-858.
80. Maes M, Galecki P, Chang YS, et al. (2011) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35: 676-692.
81. Maes M, Kenis G, Kubera M, et al. (2005) The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int Immunopharmacol 5: 609-618.
82. Maes M, Kubera M, Leunis J-C, (2008) The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 29: 117-124.
83. Maes M, Mihaylova I, Leunis J-C, (2007) Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disorders 99: 237-240.
84. Maes M, Rief W, (2012) Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiat Res 196: 243-249.
85. Maes M, Smith R, Scharpe S, (1995) The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrino 20: 111-116.
86. Maes M, Song C, Lin AH, et al. (1999) Negative immunoregulatory effects of antidepressants inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacol 20: 370-379.
87. Malynn S, Campos-Torres A, Moynagh P, et al. (2013) The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 38: 694-704.
88. Massart R, Mongeau R, Lanfumey L, (2012) Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 367: 2485-2494.
89. Mendlewicz J, (2008) Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci 10: 371-375.
90. Messay B, Lim A, Marsland AL, (2012) Current understanding of the bi-directional relationship of major depression with inflammation. Biol Mood Anxiety Disord 2: 1-4.
91. Miller AH, Haroon E, Raison CL, et al. (2013) Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 30: 297-306.
92. Miller AH, Maletic V, Raison CL, (2009) Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741.
93. Miller AH, Raison CL, (2015) Are anti-inflammatory therapies viable treatments for psychiatric disorders? Where the rubber meets the road. JAMA Psychiatry 72: 527-528.
94. Miskovic M, (2015) Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy. Med Arch 69: 107-109.
95. Morgan N, Irwin MR, Chung M, et al. (2014) The effects of mind-body therapies on the immune system: meta-Analysis. PLoS One 9: e100903.
96. Morris G, Berk M, Klein H, et al. (2017) Nitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways in neuroprogressive disorders including depression and chronic fatigue syndrome. Mol Neurobiol 54: 4271-4291.
97. Muehsam D, Lutgendorf S, Mills PJ, et al. (2017) The embodied mind: A review on functional genomic and neurological correlates of mind-body therapies. Neurosci Biobehav Rev 73: 165-181.
98. Müller N, Schwarz MJ, Dehning S, et al. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatr 11: 680-684.
99. Munzer A, Sack U, Mergl R, et al. (2013) Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins 5: 2227-2240. Available at: www.ncbi.nlm.nih.gov/pubmed/24257035 (. accessed 11 July 2014).
100. Myint AM, (2012) Kynurenines: from the perspective of major psychiatric disorders. FEBS J 279: 1375-1385.
101. Myint AM, Bondy B, Baghai TC, et al. (2013) Tryptophan metabolism and immunogenetics in major depression: A role for interferon-I3 gene. Brain Behav Immun 31: 128-133.
102. Myint AM, Kim YK, (2003) Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Med Hypotheses 61: 519-525.
103. Myint AM, Steinbusch HWM, Goeghegan L, et al. (2007) Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 14: 65-71.
104. Nadjar A, Bluthé R-M, May MJ, et al. (2005) Inactivation of the cerebral NFIB pathway inhibits interleukin-1β-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 30: 1492-1499.
105. Najjar S, Pearlman DM, Alper K, et al. (2013) Neuroinflammation and psychiatric illness. J Neuroinflammation 10: 1-24.
106. O'Brien SM, Scully P, Fitzgerald P, et al. (2007) Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41: 326-331.
107. Obuchowicz E, Bielecka AM, Paul-Samojedny M, et al. (2014) Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture. Pharmacol Rep 66: 34-43.
108. Ogawa S, Fujii T, Koga N, et al. (2014) Plasma L-Tryptophan concentration in major depressive disorder. J Clin Psychiatry 75: e906-e915.
109. Pace TW, Hu F, Miller AH, (2007) Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 21: 9-19.
110. Pace TW, Miller AH, (2009) Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 1179: 86-105.
111. Pace TW, Mletzko TC, Alagbe O, et al. (2006) Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 163: 1630-1633.
112. Padol IT, Hunt RH, (2010) Association of myocardial infarctions with COX-2 inhibition. be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: An evidence-based interpretation. Rheumatology 49: 837-843.
113. Palta P, Samuel LJ, Miller ER, et al. (2014) Depression and oxidative stress: results from a meta-Analysis of observational studies. Psychosom Med 76: 12-19.
114. Pan A, Sun Q, Czernichow S, et al. (2012) Bidirectional association between depression and obesity in middle-Aged and older women. Int J Obes 36: 595-602.
115. Pasco J, Jacka FN, Williams LJ, et al. (2010) Clinical implications of the cytokine hypothesis of depression: The association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 79: 323-325.
116. Piletz JE, Halaris A, Iqbal O, et al. (2009) Pro-inflammatory biomakers in depression: Treatment with venlafaxine. World J Biol Psychiatry 10: 313-323.
117. Postal M, Appenzeller S, (2015) The importance of cytokines and autoantibodies in depression. Autoimmun Rev 14: 30-35.
118. Prins J, Olivier B, Korte SM, (2011) Triple reuptake inhibitors for treating subtypes of major depressive disorder: The monoamine hypothesis revisited. Expert Opin Investig Drugs 20: 1107-1130.
119. Pullen PR, Nagamia SH, Mehta PK, et al. (2008) Effects of yoga on inflammation and exercise capacity in patients with chronic heart failure. J Card Fail 14: 407-413.
120. Qin L, Wu X, Block ML, et al. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
121. Raison CL, (2014) Inflammatory depression: A trifecta of trouble. J Clin Psychiatry 75: 663-664.
122. Raison CL, (2016) The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. Curr Topics Behav Neurosci 31: 287-302.
123. Raison CL, Miller AH, (2011) Is depression an inflammatory disorder? Curr Psychiatry Rep 13: 467-475.
124. Raison CL, Rutherford RE, Woolwine BJ, et al. (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA psychiatry 70: 31-41.
125. Raivich G, (2005) Like cops on the beat: The active role of resting microglia. Trends Neurosci 28: 571-573.
126. Ramirez K, Shea DT, McKim DB, et al. (2015) Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav Immun 46: 212-220.
127. Rana I, Stebbing M, Kompa A, et al. (2010) Microglia activation in the hypothalamic PVN following myocardial infarction. Brain Res 1326: 96-104.
128. Rawdin B, Mellon S, Dhabhar F, et al. (2013) Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 31: 143-152.
129. Roomruangwong C, Kanchanatawan B, Sirivichayakul S, et al. (2016) Lower serum zinc and higher CRP strongly predict prenatal depression and physio-somatic symptoms, which all together predict postnatal depressive symptoms. Mol Neurobiol 6: 1-13.
130. Rosenblat JD, Cha DS, Mansur RB, et al. (2014) Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 53: 23-34.
131. Rosenblat JD, Kakar R, Berk M, et al. (2016) Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-Analysis. Bipolar Disord 18: 89-101.
132. Rush AJ, Fava M, Wisniewski SR, et al. (2004) Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design. Control Clin Trials 25: 119-142.
133. Rush AJ, Trivedi MH, Wisniewski S, et al. (2006) Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: A STAR∗D report. Am J Psychiatry 163: 1905-1917.
134. Samples H, Mojtabai R, (2015) Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys. Psychiatr Serv 66: 455-462.
135. Sarris J, Murphy J, Mischoulon D, et al. (2016) Adjunctive nutraceuticals for depression: A systematic review and meta-Analyses. Am J Psychiatry 173: 575-587.
136. Savitz J, Drevets WC, Smith CM, et al. (2015) Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 40: 463-471.
137. Scali C, Giovannini G, Prosperi C, et al. (2003) The selective cyclooxygenase-2 inhibitor rofecoxib supress brain inflammation from excitotoxic degeneration in vivo. Neuroscience 117: 909-919.
138. Scher JU, Pillinger MH, (2009) The anti-inflammatory effects of prostaglandins. J Investig Med 57: 703-708.
139. Schjerning Olsen A, Fosbøl EL, Lindhardsen J, et al. (2013) Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients: A nationwide study. PLoS One 8: e54309.
140. Setiawan E, Wilson AA, Mizrahi R, et al. (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72: 268-275.
141. Shelton RC, Miller AH, (2010) Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression. Prog Neurobiol 91: 275-299.
142. Shin J-Y, Park M-J, Lee SH, et al. (2015) Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 351: h3517.
143. Sluzewska A, Rybakowski JK, Laciak M, (1995) Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 762: 474-476.
144. Slyepchenko A, Maes M, Jacka FN, et al. (2017) Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. Psychother Psychosom 86: 31-46.
145. Slyepchenko A, Maes M, Köhler CA, et al. (2016) T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model. Neurosci Biobehav Rev 64: 83-100.
146. Smith RS, (1991) The macrophage theory of depression. Medical hypotheses 35: 298-306.
147. Song C, Wang H, (2011) Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 760-768.
148. Steiner J, Bielau H, Brisch R, et al. (2008) Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42: 151-157.
149. Steiner J, Walter M, Gos T, et al. (2011) Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8: 94.
150. Stockmeier C, Mahajan GJ, Konick LC, et al. (2004) Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 56: 640-650.
151. Sugama S, Takenouchi T, Fujita M, et al. (2009) Differential microglial activation between acute stress and lipopolysaccharide treatment. J Neuroimmunol 207: 24-31.
152. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, et al. (2012) Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry 2: e199.
153. Swardfager W, Rosenblat JD, Benlamri M, et al. (2016) Mapping inflammation onto mood: inflammatory mediators of anhedonia. Neurosci Biobehav Rev 64: 148-166.
154. Taraz M, Khatami M, Dashti-Khavidaki S, et al. (2013) Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. Int Immunopharmacol 17: 917-923.
155. Thayer JF, Sternberg EM, (2010) Neural aspects of immunomodulation: focus on the vagus nerve. Brain Behav Immun 24: 1223-1228.
156. Tousoulis D, Drolias A, Antoniades C, et al. (2009) Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int J Cardiol 134: 238-243.
157. Trivedi MH, Rush A, Wisniewski SR, et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 163: 28-40.
158. Tuglu C, Kara SH, Caliyurt O, et al. (2003) Increased serum tumor necrosis factor-Alpha levels and treatment response in major depressive disorder. Psychopharmacology 170: 429-433.
159. Valkanova V, Ebmeier KP, Allan CL, (2013) CRP, IL-6 and depression: A systematic review and meta-Analysis of longitudinal studies. J Affect Disorders 150: 736-744.
160. Venneti S, Lopresti BJ, Wiley CA, (2006) The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 80: 308-322.
161. Venneti S, Loprestil BJ, Wiley CA, (2013) Molecular imaging of microglia/macrophages in the brain. Glia 61: 10-23.
162. Vogelzangs N, Duivis HE, Beekman ATF, et al. (2012) Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2: e79.
163. Wohleb ES, Fenn AM, Pacenta AM, et al. (2012) Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology 37: 1491-1505.
164. Wohleb ES, Hanke ML, Corona AW, et al. (2011) β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci 31: 6277-6288.
165. Wohleb ES, McKim DB, Shea DT, et al. (2014) Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the spleen to the brain. Biol Psychiatry 75: 970-981.
166. Xia Z, DePierre JW, Nässberger L, (1996) Tricyclic antidepressants inhibit IL-6, IL-1beta and TNF-Alfa release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34: 27-37.
167. Yirmiya R, Goshen I, (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25: 181-213.
168. Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. (2009) Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 33: 722-726.
169. Zhu C-B, Blakely RD, Hewlett WA, (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-Alpha activate serotonin transporters. Neuropsychopharmacology 31: 2121-2131.
170. Zunszain PA, Anacker C, Cattaneo A, et al. (2011) Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol 35: 722-729.